Advanced Ovarian Cancer Shows Persistent Time Without Progression With Combination Niraparib/Bevacizumab

Published by W Butcher on

At an 18-month analysis of the phase 2 OVARIO trial (NCT03326193), progression-free survival (PFS) benefit persisted in a majority of patients with advanced ovarian cancer who were previously treated with frontline platinum-based chemotherapy and bevacizumab (Avastin) and went on to receive combination therapy of niraparib (Zejula) and bevacizumab. These findings were presented during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer.

Read More…

Categories: Uncategorized